Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease

Payam Emami Khoonsari(Stockholm University), Ganna Shevchenko(Uppsala University), Lars Lannfelt(BioArctic Neuroscience (Sweden)), Anna Häggmark(Science for Life Laboratory), Maria Lönnberg(Uppsala University), Jonas Bergquist(Uppsala University), Kim Kultima(Uppsala University), Peter Nilsson(Science for Life Laboratory), Martin Ingelsson(Uppsala University), Lena Kilander(British Geriatrics Society), Maria Mikus(Science for Life Laboratory)
PLoS ONE
March 7, 2016
10.1371/journal.pone.0150672
Cited by 93

Related Papers

Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
|Science|2005|2k
The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide
|PLoS ONE|2010|1k
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
|Neurology|2004|655
High levels of AAV vector integration into CRISPR-induced DNA breaks
|Nature Communications|2019|430